CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06299163
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:33.969456+00:00
Published At: 2025-07-23T00:00:00+00:00
Record Updated At: 2025-07-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Peritoneal Carcinoma", "Endometrial Cancer", "Adenocarcinoma of Lung", "Triple Negative Breast Cancer", "Liposarcoma", "Leiomyosarcoma", "Mesothelioma, Malignant", "Adenocarcinoma - Gastroesophageal Junction (GEJ)", "Adenocarcinoma of the Stomach", "Melanoma, Malignant", "Renal Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-07-23"
protocolSection.identificationModule.nctId: "NCT06299163"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.